Thursday , May 25 2017
Home / 2016 / March

Monthly Archives: March 2016

Lilly Announces Positive Results from its Late-Stage Trial of its Rheumatoid Arthritis Drug

INDIANAPOLIS, March 31, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced that detailed results of RA-BEACON — a pivotal phase 3 global study of baricitinib, a once-daily oral treatment currently under regulatory review for the treatment of moderate-to-severe rheumatoid arthritis (RA) — were …

Read More »

FDA Approves Jazz Pharmaceuticals’ Rare Liver Disease Drug

DUBLIN, March 30, 2016 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the United States (U.S.) Food and Drug Administration (FDA) granted marketing approval for Defitelio® (defibrotide sodium) for the treatment of adult and pediatric patients with hepatic VOD, also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary …

Read More »

Tesaro and MD Anderson Enter Immuno-Oncology Collaboration

WALTHAM, Mass. and HOUSTON, March 29, 2016 (GLOBE NEWSWIRE) — TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, and the Institute for Applied Cancer Science at The University of Texas MD Anderson Cancer Center today announced an exclusive collaboration to discover and develop small molecule product candidates against undisclosed immuno-oncology targets. …

Read More »

New Tool Mines Whole-Exome Sequencing Data to Match Cancer with Best Drug

A University of Colorado Cancer study published today in the Journal of the American Medical Informatics Association (JAMIA) describes a new tool that interprets the raw data of whole exome tumor sequencing and then matches the cancer’s unique genetics to FDA-approved targeted treatments. “Whole exome sequencing is becoming more available …

Read More »

FDA Panel Votes in Favor of Acadia Pharmaceuticals’ Drug for Parkinson’s Disease Psychosis

SAN DIEGO–(BUSINESS WIRE)–Mar. 29, 2016– ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 …

Read More »

IMS Health Says Surge in Biosimilars to Drive Significant Change in Health System Costs, Patient Access & Competition by 2020

DANBURY, Conn.–(BUSINESS WIRE)–Greater acceptance of biosimilar medicines in a growing number of therapy areas and an active pipeline of 56 new products in clinical development are expected to deliver total savings of as much as $110 billion to health systems across Europe and the U.S. through 2020, according to new …

Read More »

Studies Show High Out-of-Pocket Costs Limits Access to Lifesaving Specialty Drugs

PHILADELPHIA— “Specialty drugs” have become important treatment options for many serious and chronic diseases, and in some conditions like cancer they represent the only chance for long-term survival. But, insurers increasingly require patients to share the high costs of these medications. Two new studies led by researchers at the Perelman School …

Read More »

Texting For Meds

Could better medication adherence be just a “text away”? According to a new analysis taking a closer look at several previous studies about adherence, when patients receive text reminders about their medication, adherence rates go up. Way up. Looking at medication adherence data from approximately 2,700 patients with chronic diseases, …

Read More »

Forge Therapeutics and Active Motif Enter Epigenetics Research Collaboration

SAN DIEGO, March 28, 2016 /PRNewswire/ — Forge Therapeutics, Inc., a biotechnology company discovering innovative therapeutics using a breakthrough drug discovery platform targeting metalloproteins, and Active Motif, a leader in developing tools to enable epigenetics research, announced today a research collaboration aimed at advancing epigenetic research related to the family …

Read More »

Dr. Reddy’s Gains US Rights to XenoPort’s Psoriasis Candidate XP23829

HYDERABAD, India & SANTA CLARA, Calif.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and XenoPort, Inc. (NASDAQ: XNPT) announced today that they have entered into a license agreement pursuant to which Dr. Reddy’s Laboratories will be granted exclusive U.S. rights for the development and commercialization of XenoPort’s clinical-stage …

Read More »